Previous 10 | Next 10 |
The Wisconsin Department of Health Services awards Pear funding towards access to Pear’s reSET ® and reSET-O ® to patients with substance use disorder and opioid use disorder The program will support Wisconsinites on their recovery journeys with ...
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the Credit Suisse 31 st Annual Healthcare Conference in Rancho Palos Ver...
Pear Therapeutics, Inc. (the “Company”) (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced it will issue its third quarter 2022 financial results after the close of mark...
Real-world observational analysis evaluating treatment of substance use disorder (SUD) with prescription digital therapeutics (PDTs) among a large, geographically diverse population Results demonstrate the benefit of PDTs for patients to access effective SUD treatment ...
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the LifeSci Partners HealthTech Symposium on September 20, 2022. Corey McCan...
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the Morgan Stanley 20th Annual Global Healthcare Conference taking place Sep...
Camille Griffin Graham Correctional Institution, a state prison for women in Columbia, S.C., i s the first in the nation to implement FDA-authorized PDTs in a correctional setting Collaboration delivers Pear’s reSET ® and reSET-O ® , for trea...
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in Citi’s 17th Annual BioPharma Conference taking place September 7-8 in...
Lots of payors are adding reSET to their covered benefit plans, and savings results far exceed prices of the products, usually leaving about 50% in surplus for the health system. Payor contract economics is making timing issues for revenue recognition, but run-rate revenue still indic...
Pear Therapeutics, Inc. (PEAR) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Meara Murphy - Senior Director of Corporate Communications Ronan O'Brien - General Counsel and Chief Compliance Officer Corey McCann - President and Ch...